Quantify fortifies plans for expansion with two Board appointments

Published 29-MAY-2018 12:28 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Quantify Technology Holdings Limited (ASX:QFY) has announced a Board restructure as part of its broader plan to reposition itself in the intelligent buildings market.

Marking its entry into a new phase of opportunity and growth, QFY has engaged two new independent directors to bolster its expertise as it looks to broaden its global footprint in the holistic intelligent buildings market — in particular, the aged care sector.

Brett Savill brings 25 years of experience across strategy, innovation, regulation, business development and start-ups — with a particular focus on growth and acquisition.

Currently based in Sydney, Savill has held senior operational roles in Australia as well as being a former PricewaterhouseCoopers Partner in the UK. He has worked, or advised, on more than 30 M&A transactions and is an experienced Non-Executive Director.

The second appointee — who will be serving as interim Chairperson — is Lee Christensen, B.Juris., LLB, B. Comm., a commercial lawyer and former Senior Partner of Gadens with over 20 years of experience.

Based in Western Australia, Christensen brings extensive experience in the areas of banking and finance, commercial and corporate law, with a focus on guidance and advice to listed companies on issues of meeting procedure and corporate governance.

Alongside these major changes to QFY’s Board, the company is considering further appointments, and is progressing in its interview process for potential candidates with extensive business experience.

It is expected that a further appointment, specifically that of independent Director and Chairperson, will be announced in the next fortnight.

As part of the restructure, Aidan Montague has resigned as an executive director, effective immediately, to pursue other interests.

QFY remains an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.

QFY branches into global aged care market

QFY’s Board changes follow close behind the news out of the company earlier this month, that it had signed an agreement with the US-based Electronic Caregiver LLC (ECL) for the development, sales, marketing, and distribution of a collaborative solution for the US and Australian markets.

ECL offers safety and security options for the elderly and chronically ill in an effort to reduce medical complications, extend lifespan, lessen deaths, and support wellness — both through education as well as technology solutions. It gathers and analyses crucial scientific data that relates to risk assessments for the elderly and chronically ill who are either in institutional care or live independently.

QFY has stated it is partnering with ECL to enhance what the company can offer its existing client portfolio, by utilising the specific data collection and control capabilities inherent within QFY’s tech platform.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X